Company intelligence / Profile preview

CheckmAb

Ownership: Private
Development stage: Other

Overview

CheckmAb is a preclinical-stage biotechnology company developing monoclonal antibodies that selectively target tumor-infiltrating regulatory T cells, aiming to improve cancer immunotherapy outcomes. Their lead programs have demonstrated high specificity and efficacy in ex vivo and in vivo tumor models, with plans to enter clinical trials. The company has achieved significant milestones, including a major licensing agreement with Boehringer Ingelheim for one of its lead antibodies targeting TI-Tregs.

Therapeutic areas: ImmunologyOncology
Modalities: Monoclonal antibodyAntibody (general)
Industry: Biotech

Drug pipeline

1 asset

Checkmab intratumoral Treg-depleting monoclonal antibodies

Preclinical

Partnerships

Boehringer Ingelheim (strategic collaboration and license agreement for development of first-in-class mAbs for cancer immunotherapy)

Beyond the preview

Go deeper on CheckmAb.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CheckmAb.

Explore the full profile